l Ibrutinib may be associated with invasive fungal infections especially IA.
Introduction
Infections still represent an important cause of morbidity and mortality in chronic lymphocytic leukemia (CLL). Impaired humoral and cellular immunity related either to CLL itself or to its treatments, corticosteroid use, and chronic neutropenia are risk factors. Invasive fungal infections (IFI) are rare in CLL, and most cases have been described in previously heavily pretreated patient.
Ibrutinib has revolutionized the therapeutic strategy of CLL. [1] [2] [3] Clinical trials suggest ibrutinib is associated with fewer infectious complications than standard chemotherapy. Recently, 5 cases of Pneumocystis jirovecii pneumonia in a cohort of 96 CLL patients treated with single-agent ibrutinib have been reported. 4 Four out of 5 patients were treatment naïve suggesting that ibrutinib per se may be a risk factor for Pneumocystis infection. Other IFIs, in particular invasive aspergillosis (IA), have been described in several case reports. [5] [6] [7] Recently, an unexpected number of IA cases were observed in 2 randomized controlled trials in patients receiving ibrutinib for primary central nervous system (CNS) lymphoma. 8, 9 These data and several personal observations of IFI cases in patients receiving ibrutinib for CLL prompted us to address the question of a potential association of IFI with ibrutinib.
Here we report the results of a retrospective survey in France in which 33 cases of IFI were identified in patients receiving ibrutinib alone or in combination. Our data suggest that mold infections caused by Aspergillus species are the most frequently occurring IFI in patients treated with ibrutinib, with very frequent cerebral localizations, followed by disseminated cryptococcosis. Remarkably, the vast majority of IFI occurred within the first 3 months of treatment.
Study design
We conducted a multicenter survey aimed at identifying cases of IFI among centers of the French Innovative Leukemia Organization CLL group. This study was conducted in accordance with the Declaration of Helsinki and was approved by a local ethics committee. Anonymized data were collected retrospectively with the help of a standardized case report form. Between 2013 and 2017, 33 cases of IFI from 16 French centers were identified, including 2 previously published cases. 6 
Results and discussion
Patients' characteristics are shown in Table 1 . Thirty patients had CLL, including 15 with 17p deletion. One had mantle cell lymphoma and 2 Waldenström macroglobulinemia. Median number of previous treatments was 2 (range 0-4). Previous treatments consisted of immunochemotherapy. Three patients had received alemtuzumab .3 years before ibrutinib. None had undergone stem cell transplantation. All but 1 patient received ibrutinib for a relapsed/refractory disease. Median time between last treatment and ibrutinib was 10.5 months (range 1-96). Additional predisposing factors were present in the majority of patients. IA accounted for the majority of IFIs (27/33), including 11 cases (40.7%) with CNS localizations (Figure 1 ). Using European Organisation for Research and Treatment of Cancer criteria, 17 cases were proven, 9 probable and only 1 possible. We also observed 4 cases of disseminated cryptococcosis, 1 mucormycosis, and 1 Pneumocystis pneumonia. Median time between ibrutinib initiation and IFI diagnosis was 3 months (range 1-30). Twenty-eight cases were diagnosed within 6 months with 20 cases occurring #3 months. Only 2 patients had very late-onset pulmonary aspergillosis, occurring after 15 and 30 months, respectively. The diagnosis of IFI resulted in ibrutinib discontinuation in 21 patients. In the others, ibrutinib was either continued at a lower dose because of interactions between ibrutinib and voriconazole or resumed after resolution of the IFI. At last follow-up, 17 patients had died either from IFI (9), CLL (5), or unrelated causes (3).
Epidemiological data on fungal infections in CLL are scarce and usually predate the advent of targeted therapies. IFIs seem rare in newly diagnosed CLL patients. 10 In the prospective 2005 to 2007 French study, CLL accounted for 6.6% of the 393 probable or proven cases of IA. 11 In the Prospective Antifungal Therapy Alliance registry, CLL patients accounted for 7.1% of the entire hematologic cohort with aspergillosis. 12 In a large monocentric study in 1191 adult patients with B-cell malignancies, the rates of IFI and IA in the 305 patients with CLL were much lower, 1.3% and 14 Sporadic cases of IA or cryptococcosis occurring in CLL patients during ibrutinib therapy have been reported. [5] [6] [7] In addition, an unexpectedly high incidence of invasive pulmonary and cerebral aspergillosis was observed in patients enrolled in 2 clinical trials treated with ibrutinib for relapsing/refractory primary CNS lymphoma. 8, 9 These cases raised concerns about the imputability of ibrutinib 15 inasmuch as IA was considered to be a very rare complication in patients with primary CNS lymphoma despite frequent exposure to high-dose corticosteroids. 16 A similar warning was also issued by Chamilos et al, who reviewed all cases of IFI reported in patients receiving ibrutinib or other small-molecule kinase inhibitors. 17 Interestingly, most of our cases appear to follow a common pattern, which closely resembles the recent series of Ruchlemer et al. 18 First, most IFIs had an early onset, suggesting that impairment of antifungal responses occurs rapidly before the immune reconstitution that has been observed with prolonged ibrutinib treatment. 19 Second, IA was overrepresented (80%) with a strikingly high incidence of CNS involvement. Finally, other factors that may have contributed to IFI were frequently associated. This has also been observed in other reports. 7, 9, 18 Altogether, this suggests ibrutinib alone may not in most cases be sufficient for IFI development, but its effect can be unmasked when an underlying immune deficiency is associated. This might explain in part why nearly all cases were relapsed/refractory disease, as these patients are potentially more immunosuppressed than first-line patients.
Increased risk of IFI was not apparent in the results of the initial clinical studies on ibrutinib in CLL. 20 Our results and that of others confirm that ibrutinib may be associated with IFI in real life. Although our study was not designed to determine an incidence, IFI seem infrequent considering the number of patients who received ibrutinib for the last 4 years in France. This is consistent with data from Ohio State University. 21 Opportunistic infections were identified in 23/566 ibrutinibexposed patients (4.1%), IFI representing nearly half the cases.
How ibrutinib may decrease antifungal immunity remains to be clarified. Multiple mechanisms may be involved (supplemental Figure 1 ; available on the Blood Web site). In mice, Btk plays an important role in neutrophil differentiation and function. 22 Upon phagocytosis, Aspergillus fumigatus activates a TLR9-BTKcalcineurin-NFAT pathway. 23 Btk 2/2 mice exposed to Aspergillus fumigatus have a higher mortality rate than mice with wild-type Btk. 9 However, humans with X-linked agammaglobulinemia, caused by inactivating Btk mutations, are not susceptible to fungal infections. 24 An off-target effect outside Btk inhibition may also be considered. For example, ibrutinib strongly inhibits For personal use only. on August 4, 2018. by Fredrik Schjesvold www.bloodjournal.org From platelet degranulation, which has been shown to attenuate the virulence of Aspergillus species in vitro. 25 In conclusion, our data confirm that ibrutinib may be associated with the development of IFI, in particular IA. IFIs tend to occur within the first months of treatment and are infrequent thereafter. Although it seems difficult at this point to advocate for systematic antifungal prophylaxis in all patients, an increased awareness about the potential risk of IFI after initiating ibrutinib is warranted, especially when other predisposing factors are associated. Further prospective epidemiological studies will help determine the actual risk of IFI in patients treated with ibrutinib or other Btk inhibitors.
